A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics
of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's
lymphoma or chronic lymphocytic leukemia. In a dose-expansion part, GDC-0853 will be assessed
in subsets of patients.